Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Aosaikang Licenses Adlai Nortye’s Pan-RAS Inhibitor AN9025 for China in $100 Million Deal

Fineline Cube Dec 31, 2025
Company Deals

NeuroGen Pharma Invests RMB 80 Million in GBA Medical Park for Neurology Expansion

Fineline Cube Dec 31, 2025
Company Deals

Zelgen Licenses ZG006 to AbbVie for $1.2 Billion in Milestones Ex-China

Fineline Cube Dec 31, 2025
Company Deals

Ribo Life Science Raises HK$1.6 Billion in Hong Kong IPO for siRNA Pipeline

Fineline Cube Dec 31, 2025
Company Deals

Broncus Medical Acquires Valgen Stake from Venus for $15 Million

Fineline Cube Dec 30, 2025
Policy / Regulatory

Haihe Biopharma’s Risovalisib Enters China SPARK Project for Pediatric PIK3CA Disorders

Fineline Cube Dec 30, 2025
Company Drug

HutchMed’s Savolitinib NDA Accepted by NMPA for MET-Amplified Gastric Cancer with Priority Review

Fineline Cube Dec 31, 2025
Company Drug

Sirius Therapeutics Doses First Phase II Patient for SRSD216 siRNA Hyperlipoproteinemia Therapy

Fineline Cube Dec 31, 2025
Company

MicroPort Scientific Reports 19% Revenue Growth in H1 2023, Driven by Diverse Interventions

Fineline Cube Sep 22, 2023

Shanghai-based medical device giant MicroPort Scientific Corp. (HKG: 0853) has released its financial report for...

Company R&D

Amgen Launches Global Collaboration Network to Advance Oncology Research

Fineline Cube Sep 22, 2023

Amgen (NASDAQ: AMGN) has announced the launch of a new collaboration network that connects its...

Company Deals

Roche’s Genentech Partners with Orionis Biosciences for Molecular Glue Therapies

Fineline Cube Sep 22, 2023

Genentech, a subsidiary of Swiss pharmaceutical giant Roche (SWX: ROG), has announced a partnership with...

Company Drug

Suzhou Zelgen Biopharmaceuticals’ ZG005 Receives NMPA Approval for Solid Tumor Trial

Fineline Cube Sep 22, 2023

Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266), a China-based pharmaceutical company, has announced that it...

Company Drug

Antengene’s Anti-CD24 Antibody ATG-031 Gets Green Light for Phase I Study at MD Anderson

Fineline Cube Sep 22, 2023

Antengene Corporation Ltd (HKG: 6996), a China-based biopharmaceutical company, has announced that the Institutional Review...

Company Deals

Inmagene Biopharmaceuticals and Aditum Bio Launch JV Celexor Bio to Target Autoimmune Diseases

Fineline Cube Sep 22, 2023

Inmagene Biopharmaceuticals, a China-based biopharmaceutical company, has announced a strategic collaboration with US firm Aditum...

Company Drug

Mabwell Bioscience’s 9MW3011 Earns US FDA Fast Track Designation for Polycythemia Vera Treatment

Fineline Cube Sep 22, 2023

Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a China-based biopharmaceutical company, has announced that it...

Company Medical Device

Sansure Biotech Secures CE Mark for 60 Molecular Diagnostic Products, Including Procalcitonin Assay Kit

Fineline Cube Sep 22, 2023

Sansure Biotech Inc., a leading molecular diagnostics specialist based in China (SHA: 688289), has announced...

Company Deals

Abbott Expands Biosimilars Portfolio with mAbxience In-License Agreement

Fineline Cube Sep 21, 2023

Abbott (NYSE: ABT) has announced the in-licensing of several biosimilar drugs from Spain-based biotechnology firm...

Company Deals

Merck Forges Partnerships with BenevolentAI and Exscientia for Precision Drug Discovery

Fineline Cube Sep 21, 2023

German pharmaceutical company Merck (NYSE: MRK) has announced two separate strategic collaborations with UK-based artificial...

Company Drug

Novartis’s Aimovig Approved by China’s NMPA for Preventive Migraines Treatment

Fineline Cube Sep 21, 2023

Swiss pharmaceutical giant Novartis (NYSE: NVS) has announced that it has received market approval from...

Company Drug

Organon’s Liptruzet Approved in China for Hypercholesterolemia Treatment

Fineline Cube Sep 21, 2023

US-based Organon (NYSE: OGN) has announced that it has received market approval from the National...

Company

WuXi XDC Expands Manufacturing Capacity with New GMP Facilities in Wuxi

Fineline Cube Sep 21, 2023

WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA,...

Policy / Regulatory

CDE Releases 74th Batch of Generic Reference Preparations with 58 New Specifications

Fineline Cube Sep 21, 2023

The Center for Drug Evaluation (CDE) has released the 74th batch of chemical generic reference...

Company Deals

Roche’s Genentech Partners with Peptidream for First-in-Class PDCs in Radioisotope Therapy

Fineline Cube Sep 21, 2023

Swiss pharmaceutical giant Roche’s subsidiary, Genentech (SWX: ROG), has announced a partnership with Japan’s peptide-based...

Company Deals

Lynk Pharmaceuticals Secures Series C2 Financing to Advance pipeline

Fineline Cube Sep 21, 2023

Lynk Pharmaceuticals Co., Ltd, a China-based pharmaceutical company, has announced the successful completion of its...

Company Drug

Hainan Poly Pharm Submits DMF for Tecovirimat API to US FDA

Fineline Cube Sep 21, 2023

China-based Hainan Poly Pharm Co., Ltd (SHE: 300630) has announced the filing of a Drug...

Company Legal / IP

South Africa’s Competition Commission Investigates J&J for MDR-TB Drug Pricing and Evergreening

Fineline Cube Sep 21, 2023

The Competition Commission of South Africa has announced an investigation into Johnson & Johnson (J&J;...

Company Drug

Tonghua Golden-Horse’s Octohydroaminoacridine Succinate Meets Phase III Endpoints in Alzheimer’s Disease

Fineline Cube Sep 21, 2023

China-based Tonghua Golden-Horse Pharmaceutical Industry Co., Ltd. (SHE: 000766) has announced positive results from its...

Policy / Regulatory

China’s NHC Expands Rare Disease List, Includes 21 Cancer Types

Fineline Cube Sep 21, 2023

The National Health Commission (NHC) of China has released an updated national list of rare...

Posts pagination

1 … 406 407 408 … 603

Recent updates

  • Aosaikang Licenses Adlai Nortye’s Pan-RAS Inhibitor AN9025 for China in $100 Million Deal
  • HutchMed’s Savolitinib NDA Accepted by NMPA for MET-Amplified Gastric Cancer with Priority Review
  • NeuroGen Pharma Invests RMB 80 Million in GBA Medical Park for Neurology Expansion
  • Zelgen Licenses ZG006 to AbbVie for $1.2 Billion in Milestones Ex-China
  • Sirius Therapeutics Doses First Phase II Patient for SRSD216 siRNA Hyperlipoproteinemia Therapy
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Aosaikang Licenses Adlai Nortye’s Pan-RAS Inhibitor AN9025 for China in $100 Million Deal

Company Drug

HutchMed’s Savolitinib NDA Accepted by NMPA for MET-Amplified Gastric Cancer with Priority Review

Company Deals

NeuroGen Pharma Invests RMB 80 Million in GBA Medical Park for Neurology Expansion

Company Deals

Zelgen Licenses ZG006 to AbbVie for $1.2 Billion in Milestones Ex-China

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.